March Budget Surplus Shrinks to €209 Million as €1.06 Billion in SNS Debt-Regularization Hits the Books — IRC Drops 25.4%, Investment Spending Climbs 53.6%, and the Headline Hides a Real Improvement

Portugal's general-government surplus came in at €209 million for the month of March 2026 — down €1,399 million year-on-year — according to the cash-basis execution release published Thursday by the Entidade Orçamental, the body that consolidates the public-accounts data. The headline number is the worst monthly comparison since the pandemic-era distortions of 2020 and 2021. The footnote is that almost the entire deterioration is one item: a €1,059 million debt-regularization payment from SNS entities to suppliers in March, drawn against a €1,230 million capital injection the Government had previously announced for the hospitals and primary-care network.

Strip the SNS payment out of the column and the underlying budget picture is far less dramatic. Adjusted for the regularization, the surplus shrank by roughly €340 million year-on-year — which is consistent with the Stability Programme update sent to Brussels earlier this week, the one that revised the 2026 fiscal target from a 0.1% surplus to a null balance.

SNS Did the Damage — and It Was Designed to

The capital injection is the same one the Health Ministry announced in March as part of the 2026 Health Convergence framework: a transfer of €1,230 million to clear backlogged invoices to private hospitals, pharmacies, medical-device suppliers and outsourced clinical providers that had built up across SNS hospitals and ARS regional administrations through 2024 and 2025. The €1,059 million figure now in the March accounts is the portion of that envelope actually paid through to suppliers in the month — the rest will land across April and May.

Importantly for European Statistical Office accounting, the regularization does not affect the underlying SNS deficit position. The cash hits the surplus line on a cash-flow basis, but the corresponding accruals were already booked in earlier periods — meaning that under the ESA-2010 accrual standard the EU uses for excessive-deficit-procedure scoring, March's cash payment is broadly neutral. The Government's Brussels submission this week is the version that matters for surveillance.

The Underlying Picture: Revenue +6.1%, Spending +7.8%

Revenue grew 6.1% in the cumulative January–March window, with fiscal revenue up 1.3% to €13,778 million. The single largest signal in that print is the sharp drop in corporate-income tax (IRC) collections, down 25.4% — almost entirely a refunds story rather than a profitability shock, with this year's refund cycle running heavier than the 2025 baseline as more 2024 corporate filings clear the AT's processing queue. Personal-income tax (IRS) collections rose 3.1%, broadly tracking nominal-wage growth and the residual drag of the 2026 mid-bracket cut. VAT collections climbed 1.3% on the same refund-corrected basis.

Social contributions led the revenue side at 7.4% growth, with Social Security alone up 7.8% on the contribution-base side — a function of strong employment growth (5.07 million in the latest INE labour-force read) and the 5.7% minimum-wage uplift that flows directly to the contribution base.

On the expenditure side, the headline 11.9% increase narrows to 7.8% adjusted for the SNS regularization. The most striking sub-line in the cumulative window is investment spending, which climbed 53.6% — the surge reflects accelerated PRR drawdown in advance of the August 2026 final-disbursement window and the front-loading of storm-related infrastructure repair work. Goods-and-services acquisitions grew 38.1% headline (5.9% ex-SNS); personnel costs were up 6.6%; transfers up 7%; and interest charges up 3.9%, the slowest-growing major category as the rate cycle peaks.

The SNS Itself Stays in Deficit

The SNS posted a €224.6 million deficit for the month of March itself — €25 million worse than March 2025. Including the capital allocation, the cumulative SNS balance now stands at a roughly €1.005 billion deficit position, about a third worse than the 2025 trajectory. The mid-year Health Convergence review in July will be the next political pressure point: if the deficit trajectory does not bend, the framework will need either supplementary state injections or operational-cost compression — neither of which is politically straightforward in the run-up to the OE 2027 negotiations that begin in September.

What This Means for Expats

• The Brussels submission is the real number. The €209 million surplus headline is a cash-basis distortion. The Stability Programme's null-balance trajectory for 2026 is the figure that matters for euro-area surveillance and credit ratings. DBRS, Fitch and Moody's are unlikely to react to the March print.
• The SNS bill is structural, not one-off. Despite the €1.23 billion regularization, the SNS keeps generating monthly deficits. Foreign residents using the public system can expect continued procurement-led tightening through the second half of the year — particularly on private-hospital outsourcing arrangements that the regularization was supposed to repair.
• IRC refunds are catching up. The 25.4% IRC drop is a one-quarter optical effect — the AT is clearing the refund backlog from 2024 corporate filings. Foreign-owned Portuguese companies waiting on IRC reimbursements should see faster turnaround through Q2.
• Public investment is moving. The 53.6% investment-spending jump is real. PRR-funded works on rail, water, energy storage and digital infrastructure are accelerating — a signal that contractor pipelines and public-works employment are on a stronger trajectory through summer 2026.
• Social Security stays well-funded. The 7.4% growth in contributions, combined with employment near record levels, means the social-security system is comfortable on the inflow side. The reform conversations in Lisbon are about long-term ratios, not short-term liquidity.

The next monthly execution release lands at the end of May with April data, and will be the first read on whether the SNS regularization has held or whether further injections are coming through the second quarter.